Holter and ECG Changes After Transcatheter Closure Of ASD In Children

Sponsor
Sohag University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05540769
Collaborator
(none)
50
1
1
12
4.2

Study Details

Study Description

Brief Summary

Atrial septal defects (ASD) account for 10% of all congenital heart defects [1].

Hemodynamic consequences of an ASD are dilatation of the right atrium and right ventricle (RV) because of the volume overload due to the left-to-right shunt through the ASD.For several decades, surgical closure has been considered the standard method of repairing a secundum ASD [2]. Surgical repair, albeit enjoying a high success rate, negligible mortality, and good long-term outcome, is associated with morbidity, discomfort, and thoracotomy scars [3]. That is why the transcatheter closure of the ASD has more recently become an alternative to the surgical procedure [4].

During the last decade , ASD device closure , has finally replaced surgical ASD repair in most patients as the standard method of repair for the secundum ASD[5,6].

Cardiac arrhythmias and right chamber enlargement are well known long-term sequelae of atrial septal defect (ASD) [7]. Therefore, many authors suggest ASD closure before adulthood [8,9].

Classical ECG findings for a significant ASD are prolongation of the PR interval, prolongation of the QRS duration and right axis deviation of the QRS [10].

Percutaneous ASD closure is an ideal situation to study changes of RV dimensions and their impact on ECG as interferences from cardiopulmonary bypass, cardiac incisions and sutures on the right atrium and on the interatrial septum are excluded[11].

Condition or Disease Intervention/Treatment Phase
  • Procedure: catheter guided ASD closure
N/A

Detailed Description

The Aim Of Work:

The focus of this study is to describe the electrocardiography (ECG) changes 1,6,12 months after ASD transcatheter device closure in a pediatric population.

Patients and Method:
  • Place of the Study: Cardiac catheterization unit , pediatric department , Sohag university hospital .

  • Type of the Study: Prospective observational study.

  • Study Period: 12 months (starting from the date of obtaining the approval from the research ethics committee) .

  • Patients:

  • Inclusion Criteria:

  • All children under the age of 18 years diagnosed with ASD , that will undergo transcatheter secundum ASD device closure during the period of the study .

  • Exclusion Criteria:

  • Failure to obtain informed consent .

Ethical consideration Approval will be obtained from the medical research ethics committee (MREC) of faculty of medicine Sohag university .Informed consent will be obtained from parent or authorized legal representative of all children included in the study .

  • Methods of the Study:

  • The following data will be collected from all patients:

*Demographic data:

  • Name , Age , sex and Residence .

*Medical history:

  • General medical history will be obtained .

  • All patients will be subjected to :

  • 12 leads ECG (Fukuda Denshi CardiMax ECG device model FCP-7101 with a 25 mm/s paper speed, gain 10 mm/mV) the day before and the day after the procedure

  • Holter ECG (Mortara H3+ Holter ECG) the day before and the day after the procedure.

  • Clinical , ECG and Holter follow-up will be obtained at 1, 6 and 12 months respectively.

Statistical analysis:

The collected data will be statistically analyzed and expressed in tables and charts.

Conclusions and recommendations will be suggested based on the results.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Holter and ECG Changes After Transcatheter Closure Of ASD In Children
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: case group

Procedure: catheter guided ASD closure
transcatheter secundum ASD device closure

Outcome Measures

Primary Outcome Measures

  1. ECG changes in Heart rate [HR] before and after the catheter guided ASD device closure [1 month , 6 months , 1 year]

    12 leads ECG (Fukuda Denshi CardiMax ECG device model FCP-7101 with a 25 mm/s paper speed, gain 10 mm/mV) the day before and the day after the procedure -Heart rate [HR]

  2. ECG changes before and after the catheter guided ASD device closure [1 month , 6 months , 1 year]

    12 leads ECG (Fukuda Denshi CardiMax ECG device model FCP-7101 with a 25 mm/s paper speed, gain 10 mm/mV) the day before and the day after the procedure ECG PR interval , ECG QRS interval , ECG axis , and ECG corrected QT interval "QTc" will be recorded .

  3. Holter ECG changes in Heart rate [HR] before and after the ASD closure [1 month , 6 months , 1 year]

    Holter ECG (Mortara H3+ Holter ECG) changes the day before and the day after the procedure. Heart rate [HR]

  4. Holter ECG changes before and after the ASD closure [1 month , 6 months , 1 year]

    Holter ECG (Mortara H3+ Holter ECG) changes the day before and the day after the procedure. ECG PR interval , ECG QRS interval , ECG axis , and ECG corrected QT interval "QTc" will be recorded .

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    • All children under the age of 18 years diagnosed with ASD , that will undergo transcatheter secundum ASD device closure during the period of the study .
Exclusion Criteria:
    • Failure to obtain informed consent .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sohag University Hospital Sohag Egypt

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Marwa Ahmed Abdel Galil, resident doctor at pediatric department at faculty of medicine sohag university hospital, Sohag University
ClinicalTrials.gov Identifier:
NCT05540769
Other Study ID Numbers:
  • Soh-Med-22-04-19
First Posted:
Sep 15, 2022
Last Update Posted:
Sep 15, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2022